Brought to you by 
Grifols divests some Talecris assets to Kedrion SPA
06 Jun 2011
Executive Summary
To satisfy FTC merger conditions associated with its pending acquisition of Talecris Biotherapeutics Inc. (signed in 2010), Grifols SA has agreed to the sale of some of Talecris’s assets to Italian plasma production company Kedrion SPA.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Manufacturing or Supply
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com